All news items
The Telegraph | Schistosomiasis in Zambia
Article in The Telegraph on waterborne parasites that are laying eggs inside women’s bodies – with deadly consequences.
COR NTD | Innovation Lab 2022
Call for Innovations! Deadline 22 June 2022.
Share your innovation at the Annual COR-NTD Meeting, to be held virtually, 4-5 October 2022.
UK Launch of the Female Genital Schistosomiasis Integration Group (FIG)
The UK Coalition against Neglected Tropical Diseases together with the All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases co-hosted a Parliamentary reception in the House of Lords entitled Ending the Neglect: Celebrating the UK’s role in beating NTD’s. The reception launched the Female Genital Schistosomiasis (FGS) Integration Group (FIG).
Researchers begin clinical trial to assess schistosomiasis vaccine
Participant in KPWHRI trial receives world’s first-ever injection of investigational SchistoShield vaccine
Launch | Female Genital Schistosomiasis Society of Nigeria
GSA was delighted to join the Female Genital Schistosomiasis Society of Nigeria for their launch event on 30th March 2022.
WHO | Launch of new guideline for the control and elimination of human schistosomiasis
WHO launches six new recommendations for the control and elimination of human schistosomiasis
Remembering Dr Mwele Ntuli Malecela
It is with great sadness that we heard of the passing of WHO NTD Director, Dr Mwele Ntuli Malecela.
5th Cohort | COR-NTD & ARNTD Small Grants winners announced
Sixteen researchers (10 males and 6 females) from eight African countries have been selected as the fifth cohort of the Program.
RSTMH Early Careers Grants 2022 is now open for applictions
The Early Career Grants Programme 2022 is open for applications from early career researchers and global health professionals based anywhere in the world, who have not had research funding in their own name before,
WHO | Schistosomiasis: large-scale treatment decreases prevalence by 60% among school-aged children
Researchers have found that treating school-aged children periodically with praziquantel has decreased the prevalence of schistosomiasis (bilharzia) in sub-Saharan Africa by almost 60% during the past 20 years.
The Pediatric Praziquantel Consortium Announces Positive Phase III Results for Arpraziquantel To Treat Schistosomiasis
The Pediatric Praziquantel Consortium completes its pivotal clinical Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis.